CDN$ 217.88
  • List Price: CDN$ 283.99
  • You Save: CDN$ 66.11 (23%)
Only 1 left in stock (more on the way).
Ships from and sold by Amazon.ca.
Gift-wrap available.
Quantity:1
Have one to sell?
Flip to back Flip to front
Listen Playing... Paused   You're listening to a sample of the Audible audio edition.
Learn more
See this image

Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development Hardcover – Nov 10 2006


See all formats and editions Hide other formats and editions
Amazon Price New from Used from
Hardcover
"Please retry"
CDN$ 217.88
CDN$ 203.19 CDN$ 115.23

Best Canadian Books of 2014
Stone Mattress is our #1 Canadian pick for 2014. See all

Customers Who Bought This Item Also Bought



Product Details


Product Description

Review

"... There is an urgent need to understand the PK and PD characteristics of these different types of drugs. This book meets that need. ..."
Anticancer Research

From the Back Cover

The characterization and optimization of pharmacokinetic properties and exposure-response relationships are crucial parts in the drug development of biotechnologically-derived drug products. Until recently, our understanding of pharmacokinetics and pharmacodynamics was limited to 'traditional' small-molecule, non-biological drugs. Now, with the current boom in drugs based on biological molecules, such as proteins and nucleotides, there is an urgent need to understand the pharmacokinetic and pharmacodynamic characteristics of these very different types of drugs. This book meets that need.
Comprehensive in its coverage, it spans relevant topics from early phase drug development right up to late-stage clinical trials. Following an introduction to the role of PK and PD in the development of biotech drugs, the first section covers the basics, including the pharmacokinetics of peptides, monoclonal antibodies, antisense oligonucleotides, as well as viral and non-viral gene delivery vectors. The second section discusses challenges and opportunities in the pharmaceutical development of biologics, including issues related to bioanalytical assays, bioequivalence and exposure-response assessments, as well as drug delivery. The final section considers the integration of PK and PD concepts into the biotech drug development plan, taking as case studies the preclinical and clinical drug development of tasidotin, as well as the examples set by cetuximab and pegfilgrastim.
Vital reading for all pharmaceutical scientists working with biologics.

Inside This Book (Learn More)
First Sentence
During the past two decades, advances in biotechnology have triggered the development of numerous new drug products. Read the first page
Explore More
Concordance
Browse Sample Pages
Front Cover | Copyright | Table of Contents | Excerpt | Index | Back Cover
Search inside this book:

Customer Reviews

There are no customer reviews yet.
5 star
4 star
3 star
2 star
1 star


Feedback